

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



AD

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/195, 9/00		A1	(11) International Publication Number: WO 95/20953 (43) International Publication Date: 10 August 1995 (10.08.95)
(21) International Application Number: PCT/EP95/00321		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 30 January 1995 (30.01.95)			
(30) Priority Data: 9401892.6 1 February 1994 (01.02.94) GB			
(71) Applicant (<i>for all designated States except US</i>): THE BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham NG2 3AA (GB)		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): KHAN, Karrar, Ahmad [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB). SMITH, Alan [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham NG2 3AA (GB).			
(74) Agent: KIRK, Martin, John; The Boots Company plc, Patents Dept., R4 Pennyfoot Street, Nottingham NG2 3AA (GB).			

(54) Title: **THERAPEUTIC AGENTS CONTAINING THYROID HORMONES**

(57) Abstract

There is disclosed a solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration comprising: a therapeutic agent which comprises one or more compound thyroid hormone or hormones; from about 80 % to about 99.9 % of disintegrating agent by mass; from about 0.01 % to about 10 % of flavouring agent by mass; and from about 0.1 % to about 5 % mass of lubricating agent by mass; which has utility in the treatment of disorders associated with the improvement of the thyroid hormone function in animals including human beings.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

THERAPEUTIC AGENTS CONTAINING THYROID HORMONES

This invention relates to novel pharmaceutical compositions comprising one or more thyroid hormones, and to their use in the treatment of disorders 5 associated with impairment of the thyroid hormone functions in animals including human beings.

Pharmaceutical compositions comprising solid fast dispersing dosage forms for oral administration have recently become available. The dosage forms are 10 prepared by freeze drying, a relatively slow process, which involves the use of expensive and complicated equipment. Furthermore, fast dispersing dosage forms produced by freeze drying are very friable and extremely moisture sensitive, which makes them difficult to 15 package. For example, when presented in a conventional blister pack they are not sufficiently hard to retain their integrity when a force is applied to break the package seal and eject them from the blister. Such tablets are also unsuitable for conventional packing 20 into bottles. Known freeze dried fast dispersing dosage forms have the further disadvantage that they are difficult to prepare other than as large tablets.

Therefore it is an object of the invention to provide a solid fast dispersing oral dosage form for a 25 pharmaceutical composition as described herein which avoids all or some of the disadvantages of known freeze dried rapidly dispersing dosage forms whilst retaining all or some of the advantages of fast dispersing dosage forms over more conventional solid oral dosage forms.

30 These advantages include good patient compliance as fast dispersing dosage forms are easy to ingest as they

- 2 -

disintegrate readily and quickly in the mouth within seconds imparting a pleasant sensation to the mouth. This can be particularly useful for patients such as children or the elderly who have difficulty in 5 swallowing, as no extra liquid (eg water) is required to take these oral dosage forms. Fast dispersing oral dosage forms have the further advantage that the thyroid hormone active ingredient is presented to the gastro-intestinal tract in a finely divided particulate form 10 which favours optimal and consistent absorption into the body.

To improve convenience and patient compliance the oral dosage forms of the present invention may be made of a mass typically ten times smaller than possible for 15 freeze-dried dosage forms. Small oral dosage forms have the further advantage of minimising the amount of diluents ingested particularly when the therapeutic agent is present in very small amounts, for example the microgram quantities per unit dose required if the 20 therapeutic agent is thyroid hormone.

Thyroid hormones as described are useful in the treatment of disorders associated with improvement of the thyroid hormone function in animals including human beings for example myxedema, cretinism or obesity. 25 Thyroid hormones can be prepared synthetically as the biologically active L-enantiomer or can be isolated direct from the thyroid gland of animals.

Therefore the present invention provides a solid fast dispersing dosage form of a pharmaceutical 30 composition suitable for oral administration comprising: a therapeutic agent which comprises at least one thyroid hormone; from about 80% to about 99.9% of disintegrating agent; from about 0.01% to about 10% of flavouring

- 3 -

agent; and from about 0.1% to about 5% of lubricating agent, all percentages being percentage mass of ingredient by total mass of the composition (known hereinafter as 'by mass').

5 Surprisingly, the present invention provides pharmaceutical compositions giving the above stated advantages of fast dispersing oral dosage forms without freeze drying. Freeze drying is a time consuming and expensive process requiring significant capital
10 investment in specialised plant and machinery and high maintenance and operating costs. The production of the solid fast dispersing oral dosage form of the present invention by using simple formulation and processing technology results in major cost savings over production
15 of known rapidly dispersing oral dosage forms. The lubricating agent is added to the composition to aid compression of the solid dosage form. In order to improve palatability and patient compliance it has also been found that the composition must comprise a
20 flavouring agent. Solid fast dispersing oral dosage forms of the invention are less friable than freeze-dried formulations and may be made into smaller dosage forms than is possible with freeze-dried formulations. Compositions of the present invention have a suitably
25 long shelf life, and disperse in the mouth rapidly in a fine particulate form with no gritty texture. They are easy and pleasant to administer.

Thyroid hormones comprise the following:

L-3,5,3',5'-tetraiodothyronine (levothyroxine or LT4);
30 L-3,5,3'-triiodothyronine (liothyronine or LT3);
L-3,3',5'-triiodothyronine (LrT3);
L-3,5-diiodothyronine (LT2); or mixtures thereof. As used herein the term thyroid hormone should be

- 4 -

understood to include all pharmaceutically acceptable salts thereof, preferably sodium salts.

Thyroid hormones may exist as one or more polymorphic forms (for example one or more crystalline 5 forms, amorphous forms, phases, solid solutions and/or mixtures thereof) and the therapeutic agent may include each pharmaceutically acceptable polymorphic form of thyroid hormones and/or mixtures thereof.

Thyroid hormones may also exist in the form of 10 solvates (for example hydrates) and the therapeutic agent may include each solvate of thyroid hormones and/or mixtures thereof.

Preferably the therapeutic agent is present in the composition in an amount per unit dose from about 0.1 μ g 15 to about 10,000 μ g, more preferably from about 1 μ g to about 1000 μ g, most preferably, if the therapeutic agent is LT₄, from about 25 μ g to about 300 μ g.

It may be beneficial for any of the ingredients of 20 compositions of the present invention (including the therapeutic agent) to be in the form of particles of very small size, for example as obtained by fluid energy milling. Alternatively the therapeutic agent may be bound (for example by sorption, incorporation and/or 25 chemically) to nanoparticles which are colloidal polymeric particles of a size typically less than 1 micron. The distribution of such nanoparticles in the body and hence the sites of delivery of the therapeutic agent can be effected by coating the surface of the nanoparticles appropriately (for example with 30 surfactants or antibodies). The therapeutic agent in the solid dosage form of the present invention may, if

- 5 -

desired, be associated with other compatible, pharmacologically active ingredients.

Preferably the disintegrating agent comprises a blend of at least two components and each component may 5 independently comprise one or more of the following ingredients: pharmaceutical grade starch (eg maize starch), modified starch (eg pre-gelled starch and/or sodium starch glycollate), agar, bentonite, cellulose, microcrystalline cellulose, methylcellulose, carmellose, 10 croscarmellose sodium, alginic acid, guar gum, silicon dioxide and sodium lauryl sulphate; more preferably one or more of pharmaceutical grade starch and microcrystalline cellulose. Preferably the disintegrating agent is present in an amount from about 15 80% to about 99%, more preferably from about 85% to about 98% by mass of the composition.

Preferably the flavouring agent comprises one or more of the following:

a sweetening agent which may be a nutritive or non-20 nutritive sweetener preferably sodium saccharin or aspartame;
a peppermint oil and/or fruit flavour;
a flavour enhancing agent; or
an ingredient or ingredients which may induce the 25 formation of saliva, preferably a pharmaceutically acceptable acid, more preferably an organic acid, most preferably an acid selected from citric and malic acid.

Preferably the flavouring agent is present in an amount from about 0.1% to about 5%, more preferably from 30 about 1% to about 3%, by mass of the composition.

Preferably the lubricating agent is selected from one or more of the following ingredients: magnesium

- 6 -

stearate, calcium stearate, stearic acid and mixtures thereof; more preferably magnesium stearate. Preferably the lubricating agent is present in an amount from about 0.1% to about 1% by mass of the composition.

5 The disintegrating agent may be the sole diluent in the composition, or the composition may also comprise one or more additional inert diluent or diluents, which may be selected from one or more of the following ingredients: lactose, powdered sugar, sucrose, 10 pharmaceutical grade starch, kaolin, talc, and pharmaceutically acceptable calcium salts; more preferably selected from sucrose and pharmaceutical grade starch, talc, calcium phosphate and calcium sulphate. The total amount of diluent (including the 15 disintegrating agent) may be present in an amount from about 90% to about 99.9%, preferably from about 95% to about 99%, more preferably from about 95% to about 98%, by mass of the composition.

20 The solid oral dosage forms of the invention may further comprise one or more of the following optional ingredients which are pharmaceutically acceptable: binders, for example starch, gelatin, sugars (such as sucrose, molasses or lactose), and/or natural and synthetic gums (such as acacia, sodium alginate, extract 25 of Irish moss, carboxymethylcellulose, methylcellulose, ethylcellulose, polyethylene glycol, waxes, microcrystalline cellulose or polyvinylpyrrolidone); colouring agents, for example conventional pharmaceutically acceptable dyes; 30 orally acceptable preservatives; anti-oxidants; and one or more pharmaceutically acceptable effervescent couple or couples (such as an acid and a carbonate,

- 7 -

preferably sodium carbonate and/or sodium bicarbonate) to aid disintegration and improve mouth feel.

The optional ingredients may be present in an amount from a trace amount to about 10% by mass of the 5 composition.

Preferably solid oral dosage forms of the present invention may have a hardness in the range from about 1 to about 6 kp, more preferably from about 1 to about 5 kp. It will be appreciated by a person skilled in the 10 art that these ranges should not be considered as limiting, because the actual hardness of a specific solid dosage form of the present invention will vary according to the particular formulation and equipment used to prepare the dosage form. The practical limits 15 for the hardness of solid dosage forms of the invention are governed by the minimum hardness required to survive production, packaging, transport and removal from the packaging and the maximum hardness which still provides an acceptable mouth feel.

20 A further aspect of the present invention provides use of a thyroid hormone in the preparation of the pharmaceutical compositions described herein for the treating of disorders associated with an impairment of the thyroid hormone function in animals including human 25 beings.

A still further aspect of the present invention provides a method of treating disorders associated with an impairment of the thyroid hormone function in animals including human beings, which comprises administering to 30 a patient in need thereof a therapeutically and/or prophylactically effective amount of a composition according to the present invention.

- 8 -

Whilst the precise amount of the therapeutic agent administered in the treatment described above will depend on a number of factors, for example the severity of the condition, the age and past medical history of 5 the patient, and always lies within the sound discretion of the administering medical practitioner or veterinary a suitable daily dose of a thyroid hormone or administration to animals, including human beings, may generally be from about 0.1 μ g to about 10,000 μ g, 10 preferably from about 1 μ g to about 1000 μ g, more preferably if the thyroid hormone is LT₄ from about 25 μ g to about 300 μ g given in a single dose or in divided doses at one or more times during the day. Compositions of the present invention may be prepared in 15 unit dosage form, therefore each solid oral dosage form may comprise from about 0.1 μ g to about 10,000 μ g, preferably from about 1 μ g to about 1000 μ g, more preferably, if the therapeutic agent is LT₄, from about 25 μ g to about 300 μ g (for example 25 μ g, 50 μ g, 75 μ g 20 or 100 μ g) of a thyroid hormone.

Pharmaceutical compositions of the present invention may be used in adjunctive therapy with one or more other compounds having activity in the treatment of disorders associated with an impairment of the thyroid 25 hormone function in animals including human beings. It will be appreciated that the term treatment as used herein includes prophylactic use of the pharmaceutical composition of the present invention for example to protect against conditions such as hypothyroidism, in 30 animals including human beings.

The compositions of the present invention may be prepared by blending of the components or by wet or dry granulation. The blend or granulation is then compressed into tablets.

- 9 -

A yet further aspect of the present invention provides a method for the manufacture of the solid oral dosage forms of the invention comprising the steps of:

- 5 (a) forming a first mixture by blending in intimate admixture one or more disintegrant or disintegrants with a therapeutic agent comprising one or more thyroid hormone or hormones;
- 10 (b) forming a second mixture by blending in intimate admixture one or more disintegrant or disintegrants with a flavouring agent and a lubricating agent;
- 15 (c) combining the first and second mixtures to form a pharmaceutical composition; and
- (d) compressing the composition from step (c) to form a fast dispersing solid oral dosage form.

15 The invention will now be illustrated by the following non-limiting examples in which % m/m indicates the amount of ingredient is given as percentage by mass of the ingredient per total mass of the composition. The percentages may not total 100% due to rounding.

- 10 -

Example 1Fast dispersing formulation

	<u>Ingredient</u>	<u>% m/m</u>
5	Maize starch powder (disintegrant)	33.15
A	Microcrystalline cellulose (Avicel PH101) (disintegrant)	15.00
10	L-thyroxine	therapeutically effective [μ g] amounts

15	Maize starch powder (disintegrant)	34.15
	Microcrystalline cellulose (Avicel PH101) (disintegrant)	15.00
B	Citric acid powder (saliva inducing agent)	2.00
	Aspartame (sweetener)	0.2
20	Magnesium stearate powder (lubricant)	0.5

The ingredients marked A were mixed together and granulated. The powders marked B were mixed together and the resultant powder was mixed with the granules from A to coat them. Optionally permitted colours may 25 be added at this stage. The coated granules were then compressed into tablets each containing 50 μ g levothyroxine sodium on an anhydrous basis, each tablet having a hardness in the range from 1 to 3 kp. The resulting tablets were hard enough to survive in 30 conventional packaging systems such as bottles or blister packs, were insoluble and dispersed completely

- 11 -

as fine particles in the mouth within 10 to 15 seconds with a pleasant taste and a good mouth feel.

Example 2

	<u>Ingredient</u>	<u>% m/m</u>	
5	Microcrysalline cellulose (Avicel PH101)	20.00	
A	Levothyroxine sodium	Therapeutically effective amounts (μ g)	
10			
B	Maize starch powder	67.75	
	Microcrystalline cellulose (Avicel PH101)	10.00	
15	Citric acid monohydrate powder	2.50	
C	Permitted colour powder	qs	
20	D	Magnesium stearate powder	0.50

The ingredients marked A were triturated. The triturated material was mixed the ingredients marked B. The mixture of A and B was granulated with purified water and dried to form granules, which were 25 (optionally) mixed with the permitted colour (ingredient C). This mixture was finally blended with the magnesium stearate (ingredient D). The final mixture was compressed into tablets each containing 25 μ g levothyroxine sodium on an anhydrous basis, each tablet 30 having a hardness in the range from 2 to 6 kp. The resultant tablets were strong enough to survive in conventional packaging systems such as a bottle or

- 12 -

blister packs. The tablets were insoluble and dispersed completely as fine particles in the mouth within 10 to 15 seconds with a pleasant taste and mouth feel.

- 13 -

Claims

1. A solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration, the dosage form comprising: a therapeutic agent which comprises one or more thyroid hormone or hormones; from about 80% to about 99.9% of disintegrating agent by mass; from about 0.01% to about by mass 10% of flavouring agent by mass; and from about 0.1% to about 5% of lubricating agent by mass.
- 10 2. A dosage form as claimed in claim 1; in which the thyroid hormone comprises L-3,5,3',5'-tetraiodothyronine; L-3,5,3'-triiodothyronine; L-3,3',5'-triiodothyronine; L-3,5-diiodothyronine; pharmaceutically acceptable salts thereof; or any mixtures thereof.
- 20 3. A dosage form as claimed in either claim 1 or 2, in which the disintegrating agent comprises a blend of at least two components.
- 25 4. A dosage form as claimed in claim 3, in which each component independently comprises an ingredient selected from pharmaceutically acceptable starch, modified starch, methyl cellulose, agar, bentonite, cellulose, microcrystalline cellulose, alginic acid, guar gum, carboxymethylcellulose and sodium lauryl sulphate.
5. A dosage form as claimed in any preceding claim, in which composition comprises an ingredient or ingredients which induces the formation of saliva.

- 14 -

6. Use of thyroid hormone in the preparation of dosage forms as claimed in any preceding claim, for the treatment of disorders associated with impairment of the thyroid hormone function in animals including human beings.

7. A method of treating disorders associated with an impairment of the thyroid hormone function in animals including human beings, which comprises the administration to a patient in need thereof a therapeutically effective amount of a solid oral dosage form as claimed in any of claims 1 to 5.

8. A method for the manufacture of a solid oral dosage form, comprising the steps of:-

(a) forming a first mixture by blending in intimate admixture one or more disintegrant or disintegrants with a therapeutic agent comprising one or more thyroid hormone or hormones;

(b) forming a second mixture by blending in intimate admixture one or more disintegrant or disintegrants with a flavouring agent and a lubricating agent;

(c) combining the first and second mixtures to form a pharmaceutical composition; and

(d) compressing the composition from step (c) to form a fast dispersing solid oral dosage form.

25 9. A method of preparing a solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration, the method comprising: combining a therapeutic agent which comprises one or more compound thyroid hormone or hormones, with; from about 80% to

- 15 -

about 99.9% by mass of disintegrating agent and from about 0.01% to about 10% by mass of flavouring agent; followed by from about 0.1% to about 5% by mass of lubricating agent.

- 5 10. A method as claimed in claim 9; in which the thyroid hormone comprises
L-3,5,3',5'-tetraiodothyronine;
L-3,5,3'-triiodothyronine;
L-3,3',5'-triiodothyronine;
10 L-3,5-diiodothyronine;
pharmaceutically acceptable salts thereof;
or any mixtures thereof.
- 15 11. A method as claimed in either claim 9 or 10; in which the disintegrating agent comprises a blend of at least two components.
12. A method as claimed in claim 11, in which each component independently comprises an ingredient selected from pharmaceutically acceptable starch, modified starch, methyl cellulose, agar, bentonite, cellulose, 20 microcrystalline cellulose, alginic acid, guar gum, carboxymethylcellulose and sodium lauryl sulphate.
13. A method as claimed in any of claims 9 to 12, in which an ingredient or ingredients which induces the formation of saliva is added to the composition.
- 25 14. Use of thyroid hormone in a method as claimed in any of claims 9 to 13, for preparing a pharmaceutical composition for treating disorders associated with impairment of the thyroid hormone function in animals including human beings.

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/EP 95/00321

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/195 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 550 108 (AKZO N. V.) 7 July 1993 see the whole document -----	1-5, 7-12,14
X	EP,A,0 371 466 (SCHERING CORPORATION) 6 June 1990 see claims 1-10 see page 2, line 13 - line 25 see page 2, line 49 - page 3, line 17 -----	1,7-9,14



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

3

Date of the actual completion of the international search	Date of mailing of the international search report
21 April 1995	12.05.95
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/00321

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although Claim 7 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No
PCT/EP 95/00321

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0550108	07-07-93	AU-A- CA-A- JP-A- NZ-A- US-A-	3044492 2086343 5255081 245575 5324522	01-07-93 01-07-93 05-10-93 28-03-95 28-06-94
EP-A-0371466	06-06-90	US-A- AU-B- AU-A- CA-A- EP-A- JP-T- WO-A- US-A-	5073374 631584 4665489 2004033 0446298 4502318 9006136 5112616	17-12-91 03-12-92 26-06-90 31-05-90 18-09-91 23-04-92 14-06-90 12-05-92